Inovio Pharmaceuticals, Inc.【INO】 研究開発費の推移
機能の使い方
|
（単位：千ドル）
|
研究開発費
|
前年比（％）
|
|
4Q25
|
10,261
|
-20.4%
|
|
3Q25
|
13,333
|
-28.8%
|
|
2Q25
|
14,521
|
-37.1%
|
|
1Q25
|
16,090
|
-23.1%
|
|
4Q24
|
12,885
|
-25.3%
|
|
3Q24
|
18,733
|
+20.8%
|
|
2Q24
|
23,090
|
-2.8%
|
|
1Q24
|
20,913
|
-30.7%
|
|
4Q23
|
17,253
|
-59.0%
|
|
3Q23
|
15,503
|
-53.1%
|
|
2Q23
|
23,743
|
-57.9%
|
|
1Q23
|
30,176
|
-46.1%
|
|
4Q22
|
42,119
|
-54.4%
|
|
3Q22
|
33,087
|
-29.7%
|
|
2Q22
|
56,464
|
-20.3%
|
|
1Q22
|
55,978
|
+43.4%
|
|
4Q21
|
92,298
|
+250.9%
|
|
3Q21
|
47,088
|
+78.0%
|
|
2Q21
|
70,808
|
+216.4%
|
|
1Q21
|
39,044
|
+104.3%
|
|
4Q20
|
26,302
|
+19.5%
|
|
3Q20
|
26,455
|
+38.2%
|
|
2Q20
|
22,376
|
-0.5%
|
|
1Q20
|
19,111
|
-21.6%
|
|
4Q19
|
22,003
|
-16.5%
|
|
3Q19
|
19,137
|
-12.4%
|
|
2Q19
|
22,486
|
+0.1%
|
|
1Q19
|
24,389
|
-0.8%
|
|
4Q18
|
26,365
|
+7.0%
|
|
3Q18
|
21,851
|
-14.3%
|
|
2Q18
|
22,462
|
-5.9%
|
|
1Q18
|
24,577
|
+0.1%
|
|
4Q17
|
24,641
|
+3.1%
|
|
3Q17
|
25,510
|
-5.4%
|
|
2Q17
|
23,878
|
+21.6%
|
|
1Q17
|
24,542
|
+34.9%
|
|
4Q16
|
23,911
|
+53.3%
|
|
3Q16
|
26,980
|
+67.8%
|
|
2Q16
|
19,630
|
+17.6%
|
|
1Q16
|
18,189
|
+93.0%
|
|
4Q15
|
15,601
|
+68.8%
|
|
3Q15
|
16,075
|
+129.1%
|
|
2Q15
|
16,688
|
+73.7%
|
|
1Q15
|
9,426
|
+14.6%
|
|
4Q14
|
9,244
|
+44.4%
|
|
3Q14
|
7,017
|
+29.0%
|
|
2Q14
|
9,607
|
+117.8%
|
|
1Q14
|
8,225
|
+60.8%
|
|
4Q13
|
6,404
|
+44.1%
|
|
3Q13
|
5,438
|
+9.4%
|
|
2Q13
|
4,411
|
-2.6%
|
|
1Q13
|
5,115
|
+26.5%
|
|
4Q12
|
4,442
|
+6.8%
|
|
3Q12
|
4,972
|
-28.8%
|
|
2Q12
|
4,527
|
+1.4%
|
|
1Q12
|
4,042
|
-
|
|
4Q11
|
4,158
|
-
|
|
3Q11
|
6,987
|
-
|
|
2Q11
|
4,463
|
-
|